Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Eyenovia, Inc.
  6. News
  7. Summary
    EYEN   US30234E1047

EYENOVIA, INC.

(EYEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Stuart M. Grant Provides Information to shareholders of Eyenovia

06/10/2021 | 09:00am EDT

On June 10, 2021, Stuart M. Grant announced that it will be voting against Chairman Fred Eshelman and Director Ernest Mario at Eyenovia, Inc.’s 2021 annual meeting and may, from time to time, make proposals to the Company or take other actions, on his own or with other investors or potential investors, intended to increase the value of the Common Stock.


© S&P Capital IQ 2021
All news about EYENOVIA, INC.
09/15EYENOVIA : Material Definitive Agreement (Form 8-K)
PU
09/15EYENOVIA, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
08/12EYENOVIA : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08/11EYENOVIA : Announced positive topline data from its Phase 3 VISION-1 study evalu..
PU
08/11EYENOVIA, INC. : Results of Operations and Financial Condition, Other Events, Fi..
AQ
08/11Eyenovia, Inc. Reports Earnings Results for the Second Quarter Ended June 30,..
CI
08/11Eyenovia Reports Second Quarter 2021 Financial Results
GL
08/04Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11
GL
07/19EYENOVIA : to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021
BU
07/07Eyenovia to Participate in Two Upcoming Investor Conferences
GL
More news
Analyst Recommendations on EYENOVIA, INC.
More recommendations
Financials (USD)
Sales 2021 5,24 M - -
Net income 2021 -23,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,44x
Yield 2021 -
Capitalization 116 M 116 M -
Capi. / Sales 2021 22,1x
Capi. / Sales 2022 11,8x
Nbr of Employees 33
Free-Float 63,8%
Chart EYENOVIA, INC.
Duration : Period :
Eyenovia, Inc. Technical Analysis Chart | EYEN | US30234E1047 | MarketScreener
Technical analysis trends EYENOVIA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 4,46 $
Average target price 15,50 $
Spread / Average Target 248%
EPS Revisions
Managers and Directors
Sean Ianchulev President, CEO, Director & Chief Medical Officer
John P. Gandolfo Chief Financial Officer & Secretary
Fredric N. Eshelman Chairman
Luke Clauson VP-Engineering, Research & Development
Jennifer Clasby VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
EYENOVIA, INC.-26.40%116
JOHNSON & JOHNSON5.11%435 465
ROCHE HOLDING AG11.23%327 497
PFIZER, INC.21.46%251 011
NOVO NORDISK A/S49.16%231 607
ELI LILLY AND COMPANY38.43%211 895